Literature DB >> 3756943

Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.

J F Belliveau, M R Posner, L Ferrari, G W Crabtree, F J Cummings, M C Wiemann, G P O'Leary, H Griffin, M A Phaneuf, A O'Rourke.   

Abstract

Total and filterable platinum in plasma were monitored for seven courses (five patients, 25 mg/m2/day) using continuous 5-day infusions and one 30-minute infusion at a similar dose level (120 mg/m2). Maximum filterable (non-protein-bound) platinum levels (0.1-0.3 mg/L) for the extended infusions were ten to 40 times lower than that for the short-term infusion (4.0 mg/L). Filterable drug exposure as measured by the area under the [Pt]filterable-time curve is greater for the extended infusions (9.6 mg X hr/L) than that for the short-term infusion (4.8 mg X hr/L). Renal excretion of cisplatin (% of dose excreted/24-hour period after the beginning of the infusion) was measured for four courses of continuous 5-day infusions and for the 30-minute infusion. Urine excretion rates were lower for the continuous infusion (5%-8% of dose/24-hour period during the infusion) compared to the short-term infusion (33% of dose/24-hour period after the beginning of the 30-minute infusion).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756943

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

Authors:  J F Belliveau; M R Posner; G W Crabtree; A B Weitberg; M C Wiemann; F J Cummings; G P O'Leary; E Ingersoll; P Calabresi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Authors:  J L Pujol; D Cupissol; C Gestin-Boyer; J Bres; B Serrou; F B Michel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.

Authors:  Yasukazu Sagawa; Atsuya Fujitoh; Hirotaka Nishi; Hiroe Ito; Tamaki Yudate; Keiichi Isaka
Journal:  Tumour Biol       Date:  2010-11-27

4.  Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.

Authors:  Y Saito; K Mori; K Tominaga; K Yokoi; N Miyazawa
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).

Authors:  Norisuke Nakayama; Wasaburo Koizumi; Satoshi Tanabe; Tohru Sasaki; Katsunori Saigenji
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

6.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.

Authors:  Y Saito; K Mori; K Tominaga; K Yokoi; N Miyazawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer.

Authors:  H Saito; K Shimokata; M Yamamoto; H Saka; S Sakai; H Saito
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.

Authors:  E E Vokes; J A Moormeier; M J Ratain; M J Egorin; D J Haraf; R Mick; R R Weichselbaum
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.

Authors:  Sail Urien; François Lokiec
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.